Description of Research Expertise:
Pancreatic cancer, colorectal cancer, GI cancers, Phase 1, CAR T cell therapy
Selected Publications:
Maity Amit, Mick Rosemarie, Huang Alexander C, George Sangeeth M, Farwell Michael D, Lukens John N, Berman Abigail T, Mitchell Tara C, Bauml Josh, Schuchter Lynn M, O'Hara Mark, Lin Lilie L, Demichele Angela, Christodouleas John P, Haas Naomi B, Patsch Dana M, Hahn Stephen M, Minn Andy J, Wherry E John, Vonderheide Robert H: A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours. British journal of cancer : 2018.
Shabason JE, Chen J, Apisarnthanarax S, Damjanov N, Giantonio B, Loaiza-Bonilla A, O'Dwyer PJ, O'Hara M, Reiss KA, Teitelbaum U, Wissel P, Drebin JA, Vollmer C, Kochman M, Mick R, Vergara N, Jhala N, Doucette A, Lukens JN, Plastaras JP, Metz JM, Ben-Josef E.: A phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline resectable pancreatic cancer. Cancer Chemother Pharmacol. 81 (3): 609-614,2018.
Beatty Gregory L, O'Hara Mark H, Lacey Simon F, Torigian Drew A, Nazimuddin Farzana, Chen Fang, Kulikovskaya Irina M, Soulen Michael C, McGarvey Maureen, Nelson Anne Marie, Gladney Whitney L, Levine Bruce L, Melenhorst J Joseph, Plesa Gabriela, June Carl H: Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial. Gastroenterology 155 (1): 29-32,2018.
A single arm phase II study of rucapariob maintenance in patients with advanced pancreatic adenocarcinoma and a known deleterious BRCA1, BRCA2 or PALB2 mutation who have achieved stability on platinum therapy.: Reiss KA, Maxwell KN, Nathanson K, Teitelbaum UR, O’Hara MH, O’Dwyer PJ, Schneider C, Carpenter EL, Mick R, Domcheck SM. J Clin Oncol 36(4S_suppl), TPS531 : 2018.
Reiss KA, Ben-Josef E, Damjanov N, Hoteit M, O’Hara MH, Karasic TB, Teitelbaum UR, Schneider C, O’Dwyer PJ, Carpenter EL, Mick R, Vonderheide RH.: A pilot study of galunisertib (LY2157299) plus stereotactic body radiotherapy (SBRT) in advanced hepatocellular carcinoma (HCC). J Clin Oncol 36(4S_suppl), TPS528 : 2018.
Phase II trial of palbociclib in patients with advanced esophageal or gastric cancer.: Karasic TB, O’Hara MH, Teitelbaum UR, Damjanov N, Giantonio BJ, d’Entremont TS, Gallagher M, Zhang PJ, O’Dwyer PJ. J Clin Oncol, (4S_suppl), 68 36 : 2018.
Ko J, Bhagwat N, Yee SS, Ortiz N, Sahmoud A, Black T, Aiello NM, McKenzie L, O’Hara M, Redlinger C, Romeo J Carpenter EL, Stanger BZ, Issadore D: Combining machine learning and nanofluidic technology to diagnose pancreatic cancer using exosomes ACS Nano 11 (11): 11182-11193,2017.
O’Hara MH, Mick R, Lyman J, Xu J, Hosseini M, LaVallee T, Gherardini PF, Vance B, Trifan O, Dugan U, Shalabi A, Ibrahima R, Vonderheide RH.: A phase Ib/2 study of CD40 agonistic monoclonal antibody (APX005M) together with gemcitabine and nab-paclitaxel with or without nivolumab in untreated metastatic pancreatic adenocarcinoma patients. Society for Immunotherapy of Cancer (SITC), National Harbor, MD : 2017.
Ko J, Bhagwat N, Yee SS, Black T, Redlinger C, Romeo J, O’Hara M, Raj A, Carpenter EL, Stanger BZ, Issadore D: A magenetic micropore chip for rapid (<1 hour) unbiased circulating tumor cell isolation and in situ RNA analysis Lab Chip 17 (18): 3086-3096,2017.
O’Hara MH, Stashwick C, Plesa G, Tanyi JL: Overcoming barriers of CAR T cell therapy in patients with mesothelin-expressing cancers Immunotherapy 9 (9): 767-780,2017.